Stay current on changes and developments in corporate law with a wide variety of resources and tools.
July 2 — A subsidiary of the Spectranetics Corporation was awarded $20.034 million in damages after a federal judge concluded that a former director had usurped corporate opportunity by developing a competing medical device.
U.S. District Court for the Northern District of California Judge Yvonne Gonzalez Rogers found that AngioScore's co-founder Eitan Konstantino breached his fiduciary duties by not providing the company an opportunity to acquire the rights of “Chocolate,” a speciality angioplasty balloon catheter.
She also found that corporate defendants TriReme Medical Inc., a company Konstantino founded and for which he served as chief executive officer, and Quattro Vascular PTE Ltd. aided and abetted the breach for their role in launching the product. And she held QT Vascular Ltd. liable as their successor in interest.
Citing Delaware law, the court found that the corporate opportunity doctrine applies to a director who is also an inventor.
“The fact of inventorship does not absolve a director of his fiduciary obligations with respect to inventions he may develop that compete with the corporation he serves. To hold otherwise would work an absurdity,” Rogers wrote.
However, Rogers also refused to adopt a rule that obligates directors to outright give purchasing opportunities to the corporations they serve.
“Critically, holding that directors who are also innovators must relinquish to the corporations they serve technologies falling within that corporation’s line of business, in which the corporation has an interest or expectancy, or which aligns with its business purpose and objectives, would serve to undermine innovation,” she opined.
Balancing the competing policy interests of fostering innovation and a director's duty of loyalty, Rogers found that the Konstantino's duty demanded that he at least offer AngioScore the opportunity to acquire the rights to Chocolate.
He breached his fiduciary duties by not providing this opportunity, the court held, noting that he actively hid his transgression from other board members. The court held the defendants liable for AngioScore's past and future lost profits.
To contact the reporter on this story: Michael Greene in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Ryan Tuck at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/ANGIOSCORE_INC_Plaintiff_v_TRIREME_MEDICAL_INC_ET_AL_Defendants_N.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)